Ionis Pharmaceuticals Inc (IONS) stock
IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/301% below fair value
$28.01−1.05 (-3.61%)
Close on Nov 16, 2026Market cap $4.65BP/E –Yield –
Ionis Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $915.62M, up 1.6% from the year before. Over ten years it grew 14.4% a year on average. The highest annual figure on record is $915.62M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $915.62M | +1.6% |
| FY2024 | Dec 31, 2024 | $901.53M | +0.2% |
| FY2023 | Dec 31, 2023 | $899.63M | +41.0% |
| FY2021 | Dec 31, 2021 | $638.20M | +20.2% |
| FY2020 | Dec 31, 2020 | $531.00M | +15.1% |
| FY2019 | Dec 31, 2019 | $461.50M | +12.0% |
| FY2018 | Dec 31, 2018 | $411.90M | +10.6% |
| FY2017 | Dec 31, 2017 | $372.50M | +9.4% |
| FY2016 | Dec 31, 2016 | $340.40M | +6.5% |
| FY2015 | Dec 31, 2015 | $319.50M | +33.7% |
| FY2014 | Dec 31, 2014 | $238.90M | +37.5% |
| FY2013 | Dec 31, 2013 | $173.70M | +12.4% |
| FY2012 | Dec 31, 2012 | $154.60M | +1.0% |
| FY2011 | Dec 31, 2011 | $153.10M | +5.5% |
| FY2010 | Dec 31, 2010 | $145.16M | +7.8% |
| FY2009 | Dec 31, 2009 | $134.62M | +26.5% |
| FY2008 | Dec 31, 2008 | $106.44M | – |
See a number that looks wrong?